FindTrial
Sign In

Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease

Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00801268
Enrollment
300
Registered
2008-12-03
Start date
2008-11-30
Completion date
2013-11-30
Last updated
2015-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Kidney

Keywords

polycystic kidney disease, tripterygium wilfordii

Brief summary

Triptolide has been approve effective in animal model.

Detailed description

Randomized

Interventions

DRUGtripterygium wilfordii

TW，60mg/d

DRUGEmodin

100mg/d

Sponsors

Zhi-Hong Liu, M.D.
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
15 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Clinically established ADPKD * eGFR\>30ml/min. * Chinese nationality

Exclusion criteria

* Uncontrolled infections * Non-ADPKD complications

Design outcomes

Primary

MeasureTime frame
MRI calculated kidney volume, eGFREvery 3-6months

Secondary

MeasureTime frame
End-stage kidney disease (ESRD)every 2months

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026